Previous 10 | Next 10 |
JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill ® -Carbidopa/Levodopa (AP...
Gainers: Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...
Horizons ETFs Rebalances Marijuana-Focused ETFs Canada NewsWire TORONTO, July 3, 2019 TORONTO , July 3, 2019 /CNW/ - Horizons ETFs Management ( Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana L...
JERUSALEM , July 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that a review highlighting the benefits of the Accordion Pill ® (AP) oral drug delivery platform was published in the peer-reviewed journal, Therapeutic ...
Results from an open-label two-way crossover Phase 2 clinical trial evaluating Intec Pharma's (NASDAQ: NTEC ) Accordion Pill - Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients showed a treatment effect. The data were just published in the journal Parkinson's and Relat...
JERUSALEM , June 25, 2019 /PRNewswire/ --- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill ® -Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were publ...
The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...
JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) were highlighted...
JERUSALEM , May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in June. Jefferies Global Healthcare Conference Date: June 4-7, 20...
Editor's note: Seeking Alpha is proud to welcome James Mase as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Thesis Tetra...
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...